approximately 300 µg per dose. Standard concomitant therapy: Strengthening supplements according to a single and identical package for all participants under the supervision of a urologist. Safety ass

2 trials

Sponsors

Iranian academic center for education culture and research

Conditions

Condition 1: Non-obstructive Azoospermia. Condition 2: Cryptozoospermia. Azoospermia

Phase 2

Cell therapy of Non-obstructive Azoospermia and Cryptospermia

Active, not recruitingIRCT20221010056132N2

Iranian academic center for education culture and researchCondition 1: Non-obstructive Azoospermia. Condition 2: Cryptozoospermia. Azoospermia

Start: 2025-12-22Target: 60Updated: 2025-12-08

Exosome therapy of Non-obstructive Azoospermia and Cryptospermia

Active, not recruitingIRCT20251201068168N1

Iranian academic center for education culture and researchCondition 1: Non-obstructive Azoospermia. Condition 2: Cryptozoospermia. Azoospermia

Start: 2026-01-21Target: 60Updated: 2025-12-08